269 related articles for article (PubMed ID: 27307599)
1. BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer.
Bansal N; Bartucci M; Yusuff S; Davis S; Flaherty K; Huselid E; Patrizii M; Jones D; Cao L; Sydorenko N; Moon YC; Zhong H; Medina DJ; Kerrigan J; Stein MN; Kim IY; Davis TW; DiPaola RS; Bertino JR; Sabaawy HE
Clin Cancer Res; 2016 Dec; 22(24):6176-6191. PubMed ID: 27307599
[TBL] [Abstract][Full Text] [Related]
2. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F
Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984
[TBL] [Abstract][Full Text] [Related]
3. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion.
Bansal N; Davis S; Tereshchenko I; Budak-Alpdogan T; Zhong H; Stein MN; Kim IY; Dipaola RS; Bertino JR; Sabaawy HE
Prostate; 2014 Feb; 74(2):187-200. PubMed ID: 24154958
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma.
Dubrovska A; Elliott J; Salamone RJ; Kim S; Aimone LJ; Walker JR; Watson J; Sauveur-Michel M; Garcia-Echeverria C; Cho CY; Reddy VA; Schultz PG
Clin Cancer Res; 2010 Dec; 16(23):5692-702. PubMed ID: 21138868
[TBL] [Abstract][Full Text] [Related]
5. The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.
Su W; Han HH; Wang Y; Zhang B; Zhou B; Cheng Y; Rumandla A; Gurrapu S; Chakraborty G; Su J; Yang G; Liang X; Wang G; Rosen N; Scher HI; Ouerfelli O; Giancotti FG
Cancer Cell; 2019 Aug; 36(2):139-155.e10. PubMed ID: 31327655
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.
Barbieri F; Thellung S; Ratto A; Carra E; Marini V; Fucile C; Bajetto A; Pattarozzi A; Würth R; Gatti M; Campanella C; Vito G; Mattioli F; Pagano A; Daga A; Ferrari A; Florio T
BMC Cancer; 2015 Apr; 15():228. PubMed ID: 25884842
[TBL] [Abstract][Full Text] [Related]
7. Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells.
Malkomes P; Lunger I; Luetticke A; Oppermann E; Haetscher N; Serve H; Holzer K; Bechstein WO; Rieger MA
Ann Surg Oncol; 2016 Sep; 23(9):2849-57. PubMed ID: 27059026
[TBL] [Abstract][Full Text] [Related]
8. New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate.
Cui J; Hollmén M; Li L; Chen Y; Proulx ST; Reker D; Schneider G; Detmar M
Oncotarget; 2017 Jan; 8(1):1007-1022. PubMed ID: 27894093
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.
Crea F; Hurt EM; Mathews LA; Cabarcas SM; Sun L; Marquez VE; Danesi R; Farrar WL
Mol Cancer; 2011 Apr; 10():40. PubMed ID: 21501485
[TBL] [Abstract][Full Text] [Related]
10. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells.
Shimada K; Anai S; Fujii T; Tanaka N; Fujimoto K; Konishi N
J Pathol; 2013 Dec; 231(4):495-504. PubMed ID: 24549646
[TBL] [Abstract][Full Text] [Related]
11. EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB.
Civenni G; Longoni N; Costales P; Dallavalle C; García Inclán C; Albino D; Nuñez LE; Morís F; Carbone GM; Catapano CV
Mol Cancer Ther; 2016 May; 15(5):806-18. PubMed ID: 26826115
[TBL] [Abstract][Full Text] [Related]
12. BMI-1 Promotes Self-Renewal of Radio- and Temozolomide (TMZ)-Resistant Breast Cancer Cells.
Yan Y; Wang Y; Zhao P; Ma W; Hu Z; Zhang K
Reprod Sci; 2017 Dec; 24(12):1620-1629. PubMed ID: 28270035
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer.
Han Z; Wang X; Ma L; Chen L; Xiao M; Huang L; Cao Y; Bai J; Ma D; Zhou J; Hong Z
Oncotarget; 2014 Sep; 5(18):8416-28. PubMed ID: 25261365
[TBL] [Abstract][Full Text] [Related]
14. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
15. A novel hedgehog inhibitor iG2 suppresses tumorigenesis by impairing self-renewal in human bladder cancer.
Zhu L; Ni C; Dong B; Zhang Y; Shi Y; Niu H; Li C
Cancer Med; 2016 Sep; 5(9):2579-86. PubMed ID: 27465044
[TBL] [Abstract][Full Text] [Related]
16. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
17. The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing
De S; Lindner DJ; Coleman CJ; Wildey G; Dowlati A; Stark GR
Cancer Res; 2018 May; 78(9):2396-2406. PubMed ID: 29440145
[TBL] [Abstract][Full Text] [Related]
18. PMP22 Regulates Self-Renewal and Chemoresistance of Gastric Cancer Cells.
Cai W; Chen G; Luo Q; Liu J; Guo X; Zhang T; Ma F; Yuan L; Li B; Cai J
Mol Cancer Ther; 2017 Jun; 16(6):1187-1198. PubMed ID: 28336807
[TBL] [Abstract][Full Text] [Related]
19. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
20. A novel reporter construct for screening small molecule inhibitors that specifically target self-renewing cancer cells.
Shanmugam G; Mohan A; Kumari K; Louis JM; Soumya Krishnan U; Balagopal PG; George NA; Sebastian P; Maliekal TT
Exp Cell Res; 2019 Oct; 383(2):111551. PubMed ID: 31401066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
